Nachrichten und Videos - CHIASMA INC. - Englisch

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA PR Newswire NEW YORK, May 7, 2021 NEW YORK , May 7, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Chiasma, Inc. ("CHMA" or the "Company") ( CHMA ) relating to its...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chiasma, Inc. (NasdaqGS: CHMA) to Amryt (NasdaqGS: AMYT). Under the terms of the proposed transaction, shareholders of Chiasma will receive 0.396 American Depositary Shares of Amryt for each share of Chiasma that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc. PR Newswire NEW YORK, May 5, 2021 NEW YORK , May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Chiasma, Inc. (NASDAQ: CHMA) and its board of directors concerning the proposed acquisition of the company by Amryt (NASDAQ: AMYT). Stockholders will receive 0.396 Amryt American Depository Shares for each share of Chiasma stock that they hold. The transaction is expected to...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Chiasma, Inc. PR Newswire NEW YORK, May 5, 2021 NEW YORK , May 5, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Chiasma, Inc. ("Chiasma" or the "Company") (NASDAQ: CHMA) in connection with the proposed acquisition of the Company by Amryt Pharma plc ("Amryt") (NASDAQ: AMYT). Under the terms of the merger agreement, Chiasma stockholders will receive 0.396...

...

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders. Under the terms of the agreement, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares. Halper Sadeh encourages Chiasma shareholders to click here to learn more about...

Thinking about buying stock in Chiasma, Athenex, iBio, BioLineRx, or Endra Life Sciences? PR Newswire NEW YORK, May 5, 2021 NEW YORK , May 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHMA, ATNX, IBIO, BLRX, and NDRA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CHMA:...

...

WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate review of 2016 and preliminary outlook for 2017. “2016 was a challenging year for Chiasma due to our receipt of a Complete Response Letter for Mycapssa from the FDA at the time of our PDUFA date in April 2016. Despite this setback, we remain committed to developing new treatment...

WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2016. “Chiasma is committed to the development of new treatment options for acromegaly and we are currently applying all of our resources to the development of Mycapssa® (octreotide) capsules for...

Data from a Novel Patient-Reported Outcome Tool Assessing Acromegaly Treatment Satisfaction to be Presented Tools for Patients Added to Acromegaly.care WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced an upcoming presentation of a Patient Reported Outcome (PRO) tool for acromegaly at The 8th International Congress of the GRS & IGF Society in...

WALTHAM, Mass., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark J. Fitzpatrick has been appointed President and Chief Executive Officer and a member of the company’s Board of Directors, effective October 1, 2016. Mr. Fitzpatrick currently serves as Chiasma’s Chief Financial Officer. He succeeds Mark Leuchtenberger, who has stepped down as...